In contrast to its decision in Nuvo Pharmaceuticals, Inc. v. Dr. Reddy's
Laboratories Inc., which seemed to impose a higher
standard for satisfying the written description requirement, the
Federal Circuit decision in Nalpropion Pharmaceuticals, Inc. v. Actavis Labs.
FL, Inc., finds the written description requirement
satisfied under what some might call a contrived approach.
According to Chief Judge Prost's dissenting opinion, the
majority may have gone astray by treating the claim limitation at
issue as secondary to the claimed "invention."
The Contrave® Patent At Issue
The decision arose in the context of ANDA litigation surrounding
Nalpropion's weight loss drug, Contrave®
(bupropion hydrochloride; naltrexone hydrochloride). Although
several patents were at issue, written description was challenged
only for claim 11 of U.S. Patent 8,916,195: